| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―May―30 |
RAAS Overactivation and Mitochondrial Damage Signaling as Key Players in Lethal COVID-19 |
Sabrina Fulkerson, Grace Hohman, Tyler Stark, Selman Aydogdu, Mohamed Eldeeb |
| 2 |
[GO] |
2023―Jul―30 |
Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysautonomia |
|
| 3 |
[GO] |
2023―Jul―30 |
Molecular Modeling Targeting Transmembrane Serine Protease 2 (TIMPRSS2) as an Alternative Drug Target Against Coronaviruses |
|
| 4 |
[GO] |
2023―Mar―06 |
High-Throughput Screening for the Potential Inhibitors of SARS-CoV-2 with Essential Dynamic Behavior |
Zhiwei Yang, Xinhui Cai, Qiushi Ye, Yizhen Zhao, Xuhua Li, Shengli Zhang, Lei Zhang |
| 5 |
[GO] |
2022―Dec―06 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Vieira |
| 6 |
[GO] |
2022―Dec―06 |
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion |
Upinder Kaur |
| 7 |
[GO] |
2022―Nov―17 |
Coagulopathy and COVID-19 |
Victoria A. Ploplis |
| 8 |
[GO] |
2022―Oct―26 |
COVID-19 induces Cytokine Storm and Dysfunctional Hemostasis |
Victoria A. Ploplis, Jermilia Charles |
| 9 |
[GO] |
2022―Oct―18 |
ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect |
Shuainan Li |
| 10 |
[GO] |
2022―Oct―18 |
Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis |
Jyotika Rajawat |
| 11 |
[GO] |
2022―Oct―14 |
Cell Entry and Unusual Replication of SARS-CoV2 |
Francis J. Castellino, Nathan McCann |
| 12 |
[GO] |
2022―Oct―12 |
Current Drug Targets (CDT) special issue on Covid-19 and Coagulopathy Fibrinolysis in COVID-19: impact on clot lysis and modulation of inflammation |
Lirlândia P. Sousa, Michelle A. Sugimoto, Luiza O. Perucci, Luciana P. Tavares, Mauro M. Teixeira |
| 13 |
[GO] |
2022―Oct―06 |
COVID-19 and Thrombosis: Clinical Aspects |
Tetsumei Urano, Atsushi Yasumoto, Kenji Yokoyama, Hisanori Horiuchi, Eriko Morishita, Yuko Suzuki |
| 14 |
[GO] |
2022―Sep―27 |
Tissue factor and COVID-19: an update |
Nigel Mackman, Ana Teresa Azevedo Sachettor |
| 15 |
[GO] |
2022―Sep―23 |
Gastrointestinal system, COVID-19 and potential mechanisms associated with coagulopathy |
Silvio Danese, Federica Furfaro, Roberto Gabbiadini, Ferdinando D’Amico, Alessandra Zilli, Arianna Dal Buono, et al. (+2) Mariangela Allocca, Gionata Fiorino |
| 16 |
[GO] |
2022―Sep―19 |
Neurological Complications of SARS-CoV-2 Infection and COVID-19 Vaccines: From Molecular Mechanisms to Clinical Manifestations |
Manuel Yepes |
| 17 |
[GO] |
2022―Aug―27 |
Fibrinogen, Fibrin, and Fibrin Degradation Products in COVID-19 |
Kadri Kangro, Alisa S. Wolberg, Matthew J. Flick |
| 18 |
[GO] |
2022―Aug―11 |
Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia |
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Athanasios Alexiou, Gaber El-Saber Batiha |
| 19 |
[GO] |
2022―Aug―05 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Vieira |
| 20 |
[GO] |
2022―Aug―05 |
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion |
Upinder Kaur |
| 21 |
[GO] |
2022―Jul―15 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Simões e Silva |
| 22 |
[GO] |
2022―Jul―15 |
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion |
Sankha Shubhra Chakrabarti |
| 23 |
[GO] |
2022―Jun―24 |
The Role of Host-Cellular Responses in COVID-19 Endothelial Dysfunction |
Thomas E. Moran, Daniel E. Hammers, Shaun W. Lee |
| 24 |
[GO] |
2022―Apr―20 |
Current drug targets for gut microbiota biocorrection during the SARS-CoV-2 pandemic: a systematic review. |
Maria V. Sankova, Vladimir N. Nikolenko, Marine V. Oganesyan, Anastasia A. Bakhmet, Lilia V. Gavryushova, Sergey V. Sankov, Mikhail Y. Sinelnikov |
| 25 |
[GO] |
2022―Mar―17 |
Free ISG15 and protein ISGylation emerging in SARS-CoV-2 infection |
Angeles C. Tecalco Cruz |
| 26 |
[GO] |
2021―Nov―04 |
Potential implications of angiotensin-converting enzyme 2 blockades on neuroinflammation in SARS-CoV-2 infection |
Deepraj Paul, Suresh Kumar Mohankumar, Rhian S Thomas, Chai Boon Kheng, Duraiswamy Basavan |
| 27 |
[GO] |
2021―Oct―23 |
A Mechanistic Review on Plant-derived Natural Inhibitors of Human Coronaviruses with Emphasis on SARS-COV-1 and SARS-COV-2 |
Sai Krishna Guguloth, A R Lakshmi, Radhika Rajendran, Kaushik Rajaram, Thirunavukkarasu Chinnasamy, Jian-Dong Huang, et al. (+3) Hongjie Zhang, Sanjib Senapati, Siva Sundara Kumar Durairajan |
| 28 |
[GO] |
2021―Sep―07 |
Exploring the SARS-CoV-2 main protease (Mpro) and RdRp targets by updating current structure-based drug design utilizing co-crystals to combat COVID-19 |
Heena Tarannum, Sisir Nandi |
| 29 |
[GO] |
2021―Aug―09 |
Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against Coronaviruses |
Igor José dos Santos Nascimento, Edeildo Ferreira da Silva-Júnior, Thiago Mendonça de Aquino |
| 30 |
[GO] |
2021―Mar―22 |
ACE2 as a key target for treatment of COVID-19 related cardiovascular diseases: current progress and prospect |
Shuainan Li, Benzhi Cai, Wenya Ma, Fan Yang, Yan Xu, Binbin Xu |
| 31 |
[GO] |
2021―Mar―10 |
Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability utilizing Natural Agents |
Sisir Nandi, Harekrishna Roy, Asha Gummadi, Anil Saxena |
| 32 |
[GO] |
2021―Feb―16 |
Small-molecule antiviral agents in ongoing clinical trials for COVID-19 |
Çağla Begüm Apaydın, Gözde Çınar, Gökçe Cihan-Üstündağ |
| 33 |
[GO] |
2021―Jan―26 |
Role of Poly(ADP-ribose) polymerase (PARP1) in viral infection and its implication in SARS-CoV-2 pathogenesis |
Jyotika Rajawat, Abhishek Chandra |
| 34 |
[GO] |
2020―Dec―29 |
Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19 |
Amritpal Kaur, Gaurav Chaudhary, Pargat Singh, Sandeep Arora, Rajwinder Kaur |
| 35 |
[GO] |
2020―Dec―29 |
A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2 |
Mohana Das, Manish Kumar, Abhishek Jha, Kanchan Bharti, Shomedeep Mondal, Brahmeshwar Mishra |
| 36 |
[GO] |
2020―Dec―03 |
Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance |
Dinesh Singh Moirangthem, Laishram Surbala |
| 37 |
[GO] |
2020―Nov―27 |
Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection? |
Vivek Gupta, Madhan Kumar Murthy, Shripad Patil |
| 38 |
[GO] |
2020―Oct―21 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Vieira, Lucas Nery, Ludimila Martins, Luiz Jabour, Raphael Dias, Ana Cristina Simões e Silva |
| 39 |
[GO] |
2020―Oct―14 |
COVID-19 and Renal Diseases: An Update |
Letícia Bitencourt Cota, Ana Luisa Pedrosa, Stephanie Bruna Camilo Soares de Brito, Ana Cláudia Fontoura Fróes, Sarah Tayná de Carvalho, Giulio Gori Fonseca, et al. (+3) Guilherme Costa Ferreira, Pollyanna Faria Fradico, Ana Cristina Simões e Silva |
| 40 |
[GO] |
2020―Oct―07 |
Therapeutic Options for Treatment of COVID-19: A Review from Repur-posed Drugs to New Drug Targets |
Bushra Akhtar, Faqir Muhammad, Ali Sharif, Abdul Hannan |
| 41 |
[GO] |
2020―Sep―25 |
Targeting host cell proteases to prevent SARS-CoV-2 invasion |
Upinder Kaur, Sankha Shubhra Chakrabarti, Bisweswar Ojha, Bhairav Kumar Pathak, Amit Singh, Luciano Saso, Sasanka Chakrabarti |
| 42 |
[GO] |
2020―Jun―17 |
Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19 |
Md. Abdul Alim Al-Bari |
